# IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

> **NCT06324396** · PHASE1 · RECRUITING · sponsor: **Children's Mercy Hospital Kansas City** · enrollment: 15 (estimated)

## Conditions studied

- Fontan Circulation

## Interventions

- **DRUG:** Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)
- **DRUG:** Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)

## Key facts

- **NCT ID:** NCT06324396
- **Lead sponsor:** Children's Mercy Hospital Kansas City
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06324396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06324396, "IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06324396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*